InvestorsHub Logo
Followers 30
Posts 5248
Boards Moderated 0
Alias Born 10/16/2012

Re: jaytea post# 4232

Monday, 01/09/2017 7:14:20 PM

Monday, January 09, 2017 7:14:20 PM

Post# of 5007
3x1 is my guess. One of them being an acquisition OF another company. Let's see if there is something where money flows TO RXII. Having enough cash to last to Q2 2018 is only at the current burn rate. If this platform requires additional trials beyond what is on deck then cash burn will increase significantly. One has to be highly skeptical of the reasoning for the MirImmune acquisition at this point. If derma, optical, warts, etc is going so well, why move into oncology?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PHIO News